Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reply to Chris R. Cardwell, Samy Suissa and Liam J. Murray's letter to the editor re: Helene Hartvedt Grytli, Morten Wang Fagerland, Sophie D. Fosså, Kristin Austlid Taskén. Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.01.007.
Grytli HH, Fagerland MW, Fosså SD, Taskén KA. Grytli HH, et al. Eur Urol. 2013 Jul;64(1):e11-2. doi: 10.1016/j.eururo.2013.03.045. Epub 2013 Apr 11. Eur Urol. 2013. PMID: 23602404 No abstract available.
Low β₂-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism.
Braadland PR, Grytli HH, Ramberg H, Katz B, Kellman R, Gauthier-Landry L, Fazli L, Krobert KA, Wang W, Levy FO, Bjartell A, Berge V, Rennie PS, Mellgren G, Mælandsmo GM, Svindland A, Barbier O, Taskén KA. Braadland PR, et al. Among authors: grytli hh. Oncotarget. 2016 Jan 12;7(2):1878-94. doi: 10.18632/oncotarget.6479. Oncotarget. 2016. PMID: 26646591 Free PMC article.
β-Adrenergic Receptor Signaling in Prostate Cancer.
Braadland PR, Ramberg H, Grytli HH, Taskén KA. Braadland PR, et al. Among authors: grytli hh. Front Oncol. 2015 Jan 12;4:375. doi: 10.3389/fonc.2014.00375. eCollection 2014. Front Oncol. 2015. PMID: 25629002 Free PMC article. Review.
PBX3 is a putative biomarker of aggressive prostate cancer.
Ramberg H, Grytli HH, Nygård S, Wang W, Ögren O, Zhao S, Løvf M, Katz B, Skotheim RI, Bjartell A, Eri LM, Berge V, Svindland A, Taskén KA. Ramberg H, et al. Among authors: grytli hh. Int J Cancer. 2016 Oct 15;139(8):1810-20. doi: 10.1002/ijc.30220. Epub 2016 Jun 25. Int J Cancer. 2016. PMID: 27273830 Free article.
14 results